TABLE 2

Antitumor Activity of Anti-FR ¹³¹I-Labeled AFRA-DFM5.3 After Locoregional Administration in Intraperitoneal Tumor Models

					Antitumor activity over untreated animals
Experiment no.	Total dose (MBq)	Days of treatment	Treated Tumor	No. of mice	Median survival in days^*	Hazard ratio	95% Confidence limits	Survival curve P^†
1	37	+2	IGROV-1	6	33/17 (235)	0.31	0.04–0.45	0.0014
2	37	+4	IGROV-1	8	15/10 (150)	0.37	0.03–0.62	0.0105
3	37	+2	OVCAR3	8	34/14 (239)	0.23	0.01–0.16	<0.0001
	37	+4		8	31/14 (221)	0.23	0.01–0.16	<0.0001
4	37	+2	OVCAR3	6	30/22 (140)	0.23	0.01–0.26	0.0006
	55	+2		4	35/22 (160)	0.36	0.03–0.88	0.0347
5	74	+2 and +9	OVCAR3	6	>90/19 (not reached)	0.13	0.00–0.24	0.0008

↵*By 2-sided log-rank test over control mice.
↵† Ratio of median survival time in treated over control mice × 100.
Number of animals in controls ranged from 6 to 8. Data in parentheses are percentages.